New drug aims to tame fatty liver disease in 3 months
Disease control
Not yet recruiting
This study tests a new drug called SNP-610 for people with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. About 80 adults will receive either the drug or a placebo for 3 months. The main goal is to see if SNP-610 lowers liver enzyme levels and reduces liver …
Phase: PHASE2 • Sponsor: Sinew Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC